Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Key Highlights Include: A strong cash position of approximately $64 million at the end of the third quarter of 2015 following the Company's July 2015 public offering in the U.S. with gross...
-
The German Federal Institute for Drugs and Medical Devices (BfArM) has granted national marketing approval for RIZAPORT™ (RHB-103) for the treatment of acute migraines under the European...
-
TEL-AVIV, Israel, Oct. 29, 2015 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) ("RedHill" or the "Company"), an Israeli biopharmaceutical company primarily focused on late...
-
TEL-AVIV, Israel, Oct. 28, 2015 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) ("RedHill" or the "Company"), an Israeli biopharmaceutical company primarily focused on late...
-
The Phase I study with YELIVA™ (ABC294640) successfully met its primary and secondary endpoints, demonstrating that the drug is well tolerated and can be safely administered to cancer...
-
The Phase I study with YELIVA™ (ABC294640) successfully met its primary and secondary endpoints, demonstrating that the drug is well tolerated and can be safely administered to cancer...
-
TEL-AVIV, Israel, Oct. 22, 2015 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) ("RedHill" or the "Company"), an Israeli biopharmaceutical company primarily focused on late...
-
TEL-AVIV, Israel, Oct. 22, 2015 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) ("RedHill" or the "Company"), an Israeli biopharmaceutical company primarily focused on late...
-
The $225,000 U.S. National Cancer Institute ("NCI") grant was awarded to Apogee Biotechnology Corporation, from which RedHill acquired the exclusive worldwide rights to YELIVA™ (ABC294640)...
-
TEL-AVIV, Israel, Oct. 19, 2015 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) ("RedHill" or the "Company"), an Israeli biopharmaceutical company primarily focused on late...